As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

The company is also making major investments in New York, including an approximate $3.6 billion expansion ... and support facilities. Regeneron said it will be building a new fill/finish ...

On average, they are down 12.6% since the latest earnings results ... “The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin ...

Earth Day 2025 calls for a bold global effort to triple renewable electricity generation by 2030. The world of sport is ...